Cerus Corporation to Release Third Quarter 2024 Financial Results on October 30, 2024
18 Octubre 2024 - 7:30AM
Business Wire
Cerus Corporation (Nasdaq: CERS) announced today that its third
quarter 2024 financial results will be released on Wednesday,
October 30, 2024, after the close of the stock market. The Company
will host a conference call and webcast at 4:30 P.M. ET that
afternoon, during which management will discuss the Company’s
financial results and provide a general business overview and
outlook.
To listen to the live webcast and view the presentation slides,
please visit the Investor Relations page of the Cerus website at
http://ir.cerus.com. Participants may register for the call here.
While not required, interested participants are encouraged to join
10 minutes prior to the start of the event.
A replay will be available on Cerus’ website and will be
available approximately three hours after the call through Nov. 20,
2024.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the
world’s blood supply and aims to become the preeminent global blood
products company. Headquartered in Concord, California, the company
develops and supplies vital technologies and pathogen-protected
blood components to blood centers, hospitals, and ultimately
patients who rely on safe blood. The INTERCEPT Blood System for
platelets and plasma is available globally and remains the only
pathogen reduction system with both CE mark and FDA approval for
these two blood components. In the U.S., the INTERCEPT Blood System
for Cryoprecipitation is approved for the production of Pathogen
Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to
as INTERCEPT Fibrinogen Complex), a therapeutic product for the
treatment and control of bleeding, including massive hemorrhage,
associated with fibrinogen deficiency. The INTERCEPT red blood cell
system is in late-stage clinical development. For more information
about Cerus, visit www.cerus.com and follow us on LinkedIn.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241018393377/en/
Jessica Hanover Cerus Corporation 925-288-6137
Cerus (NASDAQ:CERS)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Cerus (NASDAQ:CERS)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024